Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to ...
Hosted on MSN
Amgen lifts 2026 outlook as MariTide trials expand
Amgen beat Wall Street expectations in Q1 2026 with $8.62 billion in revenue and $5.15 EPS, driven by strong growth in key drugs like Repatha and Evenity. Management raised full-year revenue and EPS ...
ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.
ByteDance's drug-discovery unit, Anew Labs, is presenting its artificial intelligence-designed therapies at international ...
The FDA has begun a pilot with AstraZeneca and Amgen to stream clinical trial data to regulators in real time, aiming to speed oversight. While the data pipeline is clear, experts warn the initiative ...
Chinese tech giant fields teams in Boston, Rio de Janeiro and Barcelona as its unit unveils frameworks and therapies powered ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
The FDA began accepting live AI and cloud data feeds from AstraZeneca's TRAVERSE and Amgen's STREAM-SCLC oncology trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results